Tequin, one of the brand names for the pharmaceutical product Gatifloxacin, was introduced to the U.S. market by Bristol-Myers Squibb in 1999. The drug, an antibiotic, was prescribed primarily for the treatment of respiratory tract infections.
In 2006, a report in the New England Journal of Medicine alleged that Tequin had been found to put users at an elevated risk for dysglycemia, a blood sugar metabolism disorder that may manifest as either hyperglycemia (high blood sugar) or hypoglycemia (low blood sugar). Initially, Bristol-Myers Squibb notified health care providers that product warnings would be enhanced. However, the company subsequently opted to terminate the manufacture of Tequin. The product is now available only as treatment for eye conditions, in the form of an eye drop.
If you experienced side effects after being prescribed Tequin, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.
Defective Drugs & Medical Devices Topics
Latest Articles
Four Types of Professional Malpractice
When you hear the word “malpractice,” what’s the first image that comes to mind? A doctor perf…
Read More 14 Dec 2018, FridaySacred Sites and Ski Resorts: The Hopi Tribe and Reclaimed Wastewater
What constitutes a “public nuisance”? And does an injury rooted in religious belief override gen…
Read More 13 Dec 2018, ThursdayField Test Fail: When Traffic Stops Go Wrong
Traffic stops on New Year’s Eve may be a good way of deterring drunk driving, but a pair of Georgi…
Read More 12 Dec 2018, Wednesday
